Physician profile
Lynn E Wingert
NPI 1992182240
$6,418.10
in general payments reported to CMS, 2019-2025
40 companies · $672 in 2025
The $672 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,273 · 2022: $1,501 · 2023: $1,552 · 2024: $1,420 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.06 | 2021-2025 | |
| Novo Nordisk INC | $1,009.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $890.82 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $498.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $439.35 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.04 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $278.31 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $264.10 | 2021-2025 | |
| Astellas Pharma US INC | $205.22 | 2021-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $141.23 | 2022-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.96 | 2021-2024 | Xifaxan, Trulance |
| Amgen INC. | $129.23 | 2022-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $74.67 | 2022-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.76 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $69.82 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $69.04 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.11 | 2022 | |
| Sanofi Pasteur INC. | $58.80 | 2023 | |
| Nestle Healthcare Nutrition INC. | $57.93 | 2022-2023 | |
| Exact Sciences Corporation | $57.07 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $52.52 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $40.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.20 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $35.51 | 2023-2024 | Rexulti |
| Aimmune Therapeutics, INC. | $32.78 | 2024 | |
| Dexcom, INC. | $32.62 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $30.86 | 2024 | Voquezna |
| Seqirus USA INC | $29.09 | 2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $24.93 | 2021 | |
| Abbott Laboratories | $23.09 | 2021 | |
| Surmodics, INC. | $22.41 | 2024 | Pounce Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight, Pounce Venous Thrombectomy System |
| Axsome Therapeutics, INC. | $20.74 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $19.63 | 2025 | Fanapt |
| Amarin Pharma, INC. | $19.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.99 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $15.88 | 2024 | Quviviq |
| Medtronic, INC. | $15.84 | 2025 | Inceptiv |
| Esperion Therapeutics, INC. | $14.97 | 2021 | |
| Eisai INC. | $13.48 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Wingert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.